The Brutal Truth About Biotech: Why $2B Per Drug Is Killing Innovation

In this a16z Podcast episode, Lada Nuzhna and Elliot Hershberg discuss the biotech industry's paradox: exploding technology amid collapsing business. They explore challenges like increasing regulation, high drug approval costs, and the rise of Chinese biotech. The conversation covers potential solutions such as AI in drug development, regulatory innovation, and focusing on novel modalities. They also address the impact of GLP-1s, the future of aging and longevity treatments, and the need for incentives to keep biotech innovation in the U.S., ultimately emphasizing the importance of inventing new approaches to maintain competitiveness and drive industry growth.